Optimization Management Study of Community Urinary Tract Infections Spectrum
NCT ID: NCT03655548
Last Updated: 2018-08-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
108 participants
OBSERVATIONAL
2016-10-01
2017-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Methodology: This prospective, multi-center, non-interventional study was conducted in collaboration with the Labazur laboratory over two 2-month periods, one without modification of the laboratory's practices, the other with the addition of documents on the CBEU report. The primary endpoint was the adequacy of prescriptions to ANSM 2015 recommendations.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Significance and Optimal Treatment of Community-onset Urinary Tract Infections Caused by Extended-spectrum β-lactamase and/or AmpC β-lactamase Producing Enterobacteriaceae
NCT01138566
Urinary Tract Infections Caused by Extended-spectrum Beta-lactamase-producing Enterobacteria
NCT06910878
Urinary Tract Infections Caused by ESBL-producing Enterobacteria
NCT03501901
Research of the Consequences on the Digestive Tract Following the Proposed Treatments for a Urinary Infection in Children
NCT03825874
Does the National Health Insurance Card Allow us to Predict Antibiotic Resistance?
NCT02292160
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* CBEU analyzed by Labazur laboratory
* CBEU positive for a spectrum β-lactamase-producing Enterobacteriaceae (ESBLE)
Exclusion Criteria
* Refusal of consent
* CBEU prescribed by a specialist
* patient hospitalised for management of the infection
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Brest
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OPTICUR-EBLSE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.